drugset / Trial / NCT02500251
Belimumab Impacting Transplant Eligibility
RandomizedSingle-groupOpen-labelTreatment
Summary
This study is a prospective, open label, phase I/II pilot study.
Timeline
- Start
- 2015-06
- Primary completion
- 2018-06
- Completion
- 2018-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Belimumab | Monoclonal antibody | — | — |
| Subject | Rituximab | Monoclonal antibody | — | — |
| Background | Bortezomib | Small molecule | — | — |